交易 Vir Biotechnology VIR

出售
 买入

VirBiotechnology 实时图表

5m 15m 30m 1h 4h 1d 1w

金融票据基础知识

Weekly Search
Weekly
Daily
日期 关闭 更改 更改(%)： 开盘价 高 低

VirBiotechnology news

number1 2025 Jul 11, 03:38

AI Podcast: Dollar Weakness and Investment Implications

number1 2025 Jul 11, 03:38

HSBC: Three 'Painful Trade' Risks Loom if Wall Street Gets It Wrong

number1 2025 Jul 11, 03:38

Turkey's $500 Billion Gold Hoard: Unlocking Economic Potential

number1 2025 Jul 11, 03:37

Brazil-US Tariffs: Trump's Intervention and Lula's Response

number1 2025 Jul 11, 00:00

AI Podcast: US & Israel's Disagreements on Iran and Gaza

最新新闻

显示更多
number1 2025 Oct 21, 00:00

Zelenskyy Expresses Doubts About Budapest as Venue for Ukraine Peace Talks

number1 2025 Oct 21, 00:00

Europe Rallies Behind Ukraine Amid Trump Pressure, Eyes Frozen Russian Assets

number1 2025 Oct 21, 00:00

US Government Shutdown: Economic Fallout and Political Impasse

number1 2025 Oct 21, 00:00

Gold Price Surge Fueled by Fed Rate Cut Expectations and Economic Uncertainty

number1 2025 Oct 19, 00:00

Global Market Overview: Precious Metals Surge Amidst Economic Uncertainty

number1 2025 Oct 18, 00:00

Japan LDP-Ishin Policy Talks: Paving the Way for a New Prime Minister?

number1 2025 Oct 18, 00:00

Israel Prepares to Reopen Rafah Crossing Amid Ceasefire Violation Claims

number1 2025 Oct 18, 00:00

Fed's Rate Cut Conundrum: An Outlook to 2026

信息

点差

0.05

点差(%)

0.7353 %

杠杆

1:10

隔夜利息（买入）

-0.0597 %

隔夜利息（卖出）

-0.0292 %

币种

USD

交易时间

市场关闭

星期五

14:31 - 20:59

星期一

14:31-20:59

星期二

14:31-20:59

星期三

14:31-20:59

星期四

14:31-20:59

分析和统计

开盘价

---

昨收

---

52 周高点/低点

--- – ---

市值

943267712

在外流通股份

139125032

财报日（下一）

0000-00-00

股息收益率

除息日

远期年度股息率

0

远期年股息率

0

每股收益

-3.62

详细了解此金融票据

Vir Biotechnology Vir Biotechnology Inc
Vir Biotechnology, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapeutic products to treat and prevent serious infectious diseases in the United States and internationally. Its clinical development pipeline consists of product investigational therapies targeting hepatitis delta virus (HDV) and other solid tumors.The company's preclinical candidates include those targeting influenza A and B, coronavirus disease 2019, respiratory syncytial virus (RSV) and human metapneumovirus (MPV), and human papillomavirus (HPV). It has grant agreements with Gates Foundation; an option and license agreement with Brii Biosciences Limited; a collaboration and license agreement with Alnylam Pharmaceuticals, Inc.; license agreements with MedImmune, LLC; and a collaborative research agreement with GlaxoSmithKline Biologicals S.A, as well as license agreement with Sanofi for three clinical-stage masked T-cell engagers (TCEs) and exclusive use of the protease-cleavable masking platform for oncology and infectious diseases. Vir Biotechnology, Inc. was incorporated in 2016 and is headquartered in San Francisco, California.

相关金融票据

资产
出售
买入
更改(%)：

立即交易

立即交易

立即交易

立即交易
相关金融票据

latest_education_articles

显示更多
Frances Wang 2025 Feb 17, 16:00

Pi network price prediction 2025: Will Pi Network price go up or down?

Stocks
Frances Wang 2025 Jan 21, 16:00

What is the XRP price prediction for 2025: Will XRP reach $1000?

Crypto
Frances Wang 2024 Dec 29, 16:00

What is the USD DXY index and how does the DXY reflect the dollar's value?

Indices
Trustpilot